|Place of Origin:||China|
|Model Number:||CAS 317318-70-0|
|Minimum Order Quantity:||Negotiation|
|Packaging Details:||10/100/250/500/1000g/foil bag|
|Delivery Time:||2-3 days|
|Payment Terms:||T/T, Western Union, MoneyGram, BTCcoin|
|Supply Ability:||1000kg per momth|
Alias : Cardarine
Synonyms : 2-(4-((2-(4-(TRIFLUOROMETHYL)PHENYL)-5-METHYLTHIAZOL-4-YL)METHYLTHIO)-2-METHYLPHENOXY)ACETIC ACID ; 2-[2-Methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]acetic Acid ; Methyl-methyl-trifluoromethylphenyl -thiazolyl-methylsulfanyl-phenoxy-acetic Acid ; 2-(4-((2-(4-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid ; GW 1516 ; 2-(2-methyl-4-((5-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)methylthio)phenoxy)acetic acid ; GW501516, Free Acid ; GSK-516 ; Antineoplastic ; SARMs ( Selective androgen receptor modulator )
CAS : 317318-70-0
Assay : > 99%
MF : C21H18F3NO3S2
MW : 453.5
MP : 134-136°C
Appearance : White powder
Product Categories : Selective Androgen Receptor ; Intermediates & Fine Chemicals ; Pharmaceuticals ; Sulfur & Selenium Compounds ; kl ; Inhibitor
Usage : It had been investigated as a potential treatment for obesity , diabetes , dyslipidemia and cardiovascular disease . GW501516 could be used by athletes as an ergogenic performance enhancing drug .
GW501516 ( also known as GW-501 ,516 , GW1516 , GSK-516 and on the black market as Endurobol ) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s , was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases , and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs .
In 2007 research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance ; the work was widely discussed in popular media , and led to a black market for the drug candidate and to its abuse by athletes as a doping agent . The World Anti-Doping Agency ( WADA ) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009 ; it has issued additional warnings to athletes that GW501516 is not safe .
GW 501516 ( Cardarine ) is one of the most versatile performance enhancers one will ever come across .
Whether you are looking to drastically increase endurance , melt fat, cut or recomp, GW will truly shine . In this article , I am going to touch on the many ways and reason to incorporate GW into every cycle that you run . There is a place for GW in every cycle , regardless of the desired goal . It can only add extra benefits that will further enhance the chances of accomplishing goals and maximizing gains .
GW-501516 is a unique medication officially classified as a PPAR receptor agonist ( PPAR-RA ) . Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline ( GSK ) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases , as well as diabetes , obesity and other conditions . It was soon discovered that the PPAR-RA was highly effective at enhancing endurance , but it was also shown to carry a high potential cost. It was discovered that GW-501516 increased the chances of cancer significantly, and as a result, GSK dropped all further research . However , the studies that produced cancerous results used doses of GW-501516 that were 500 to even 1000 times the amount that a human being would take . If cancer is a risk with standard dosing is unknown .
ENDUROBOL is a selective agonist ( activator ) of the PPARδ receptor . It displays high affinity ( Ki = 1 nM ) and potency ( EC50 = 1 nM ) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ .
It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation . It has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human .